Biovie Pharma - Transformative Therapies

A Purpose-Based Company

Through innovation, collaboration, and people- centered science, BioVie is creating new solutions enabling people to live healthier and better lives.


Focusing on Finding Solutions for Healthier Brain, Memory, and Movement

Our neurology strategy is centered at what we understand to be the nexus of biochemistry, cellular energetics, and neuroprotection, enabling us to explore the potential of our pipeline molecules to decrease inflammation, enhance glucose utilization, protect neurons, and facilitate energy transfer within the central nervous system, ultimately leading to improvements in memory and movement, and a healthier brain. Our lead Neuroscience molecule (NE3107) is currently being investigated in human clinical studies to assess its hypothesized impact on both Alzheimer’s and Parkinson’s.
Alzheimer's Innovations, Alzheimer's Disease Research​


Parkinson's Innovations | Parkinson's Disease Research​



Exploring the possibilities of improved outcomes, fewer medical burdens, and more time at home

In our cirrhosis studies, we are working to learn if our exploratory technology can help individuals who have been diagnosed with cirrhosis-related ascites (fluid that builds up inside the abdomen) to be more comfortable, to require fewer or less frequent medical procedures to drain ascites fluid, and to see if the treatment can help people with ascites to live outside of the hospital for longer periods of time.

BioVie is currently investigating BIV-201, a novel formulation of terlipressin, in human clinical trials. In BioVie’s studies of BIV-201, the exploratory medication is provided as a continuous infusion formulation delivered by a small, portable pump that the user can wear while engaging in typical tasks and activities at home.

BioVie believes that BIV-201 may have the potential to slow the build-up of ascites fluid in the abdomen, and that it may do so by constricting certain blood vessels, potentially contributing to improved blood flow in the kidneys and liver. This expected improvement may allow biological systems within the body to respond differently in the presence of BIV-201, reducing the production of ascites fluid, and lessening the “fluid in the belly” associated with cirrhosis.

Ascites / Cirrhosis​ innovations | We are targeting the disease pathway of ascites

Ascites / Cirrhosis